News Focus
News Focus
icon url

flipper44

04/10/23 7:40 AM

#583977 RE: iclight #583973

You do not understand how a conflict of interest is defined.

You just guessed “probably” what involvement 70 investigators in the trial had. Nobody cares about your guesses.

The number of patients at a site is irrelevant to authorship.

Patient level data is tabulated in the JAMA article.

Dr. Stupp is a proponent of the Optune helmet, whose data sucked. Even Dr. Stupp would not sign on to Novocure’s claims as their later articles trended more and more manipulated. Dr. Stupp is a proponent of Optune and Temodar for GBM, both result in a true survival of only about 3% at five years, but he extrapolated data from two years out to five years out to pretend he had 12% survival in the Optune trial (more likely 3% survival) but then hid the data. Follow up was discontinued after two years from last patient enrolled because survival curve was degrading.
icon url

learningcurve2020

04/10/23 8:50 AM

#583995 RE: iclight #583973

It's amazing the data was allowed to be presented the way it did, and that they somehow got JAMA to participate with just one inside person responsible for the data. And, even before getting Stupp's input.
icon url

SkyLimit2022

04/10/23 9:56 AM

#584024 RE: iclight #583973

iclight,

The independent peer review process is crucial to validating clinical data. Medical conferences are much less formal than peer review but also provide physicians the opportunity to learn about new advances in the field and the breakthroughs achieved by their peers—that’s why ASCO is always a significant and exciting event!







https://conferences.asco.org/am/industry-expert-theater





https://www.fda.gov/drugs/news-events-human-drugs/50-years-progress-treating-patients-cancer

https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/
Bullish
Bullish
icon url

Springbok80

04/10/23 10:04 AM

#584030 RE: iclight #583973

Make sure you point those conflicts out for all to read..oh wait, you cannot. For each one.